LOXL2 and neoplasm: These would include TGF‐β,[51, 54] YAP,[104] CTGF,[105] LOXL2,[106] and vascular endothelial growth factor receptor (VEGFR).[107] Furthermore, investigation of the tumor ECM proteasome, e.g., receptors mediating cell–ECM interactions or ECM domains tightly associated with cell transmembrane receptors, may lead to the discovery of novel targets to instruct the immune system cells against tumors in time and stage‐related intervention, using LNP–mRNA formulations.